Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome.
Pilala KM, Papadimitriou MA, Panoutsopoulou K, Barbarigos P, Levis P, Kotronopoulos G, Stravodimos K, Scorilas A, Avgeris M. Pilala KM, et al. Among authors: papadimitriou ma. Mol Ther Nucleic Acids. 2022 Oct 7;30:311-322. doi: 10.1016/j.omtn.2022.10.001. eCollection 2022 Dec 13. Mol Ther Nucleic Acids. 2022. PMID: 36320325 Free PMC article.
Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
Avgeris M, Tsilimantou A, Levis PK, Rampias T, Papadimitriou MA, Panoutsopoulou K, Stravodimos K, Scorilas A. Avgeris M, et al. Among authors: papadimitriou ma. Carcinogenesis. 2019 Aug 22;40(8):965-974. doi: 10.1093/carcin/bgz045. Carcinogenesis. 2019. PMID: 30815670
Circulating exosomal miRNAs: clinical significance in human cancers.
Avgeris M, Panoutsopoulou K, Papadimitriou MA, Scorilas A. Avgeris M, et al. Among authors: papadimitriou ma. Expert Rev Mol Diagn. 2019 Nov;19(11):979-995. doi: 10.1080/14737159.2019.1673732. Epub 2019 Oct 20. Expert Rev Mol Diagn. 2019. PMID: 31594418 Review.
miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome.
Papadimitriou MA, Papanota AM, Adamopoulos PG, Pilala KM, Liacos CI, Malandrakis P, Mavrianou-Koutsoukou N, Patseas D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, Terpos E, Scorilas A. Papadimitriou MA, et al. Br J Cancer. 2022 Jan;126(1):79-90. doi: 10.1038/s41416-021-01602-8. Epub 2021 Oct 30. Br J Cancer. 2022. PMID: 34718359 Free PMC article.
A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma.
Papanota AM, Karousi P, Kontos CK, Artemaki PI, Liacos CI, Papadimitriou MA, Bagratuni T, Eleutherakis-Papaiakovou E, Malandrakis P, Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, Scorilas A, Terpos E. Papanota AM, et al. Among authors: papadimitriou ma. Int J Mol Sci. 2021 Dec 5;22(23):13144. doi: 10.3390/ijms222313144. Int J Mol Sci. 2021. PMID: 34884950 Free PMC article.
Epi-miRNAs: Modern mediators of methylation status in human cancers.
Papadimitriou MA, Panoutsopoulou K, Pilala KM, Scorilas A, Avgeris M. Papadimitriou MA, et al. Wiley Interdiscip Rev RNA. 2023 Mar;14(2):e1735. doi: 10.1002/wrna.1735. Epub 2022 May 17. Wiley Interdiscip Rev RNA. 2023. PMID: 35580998 Review.
16 results